Neuroprotection in Parkinson's disease [11]

Lancet

Volumn 347, Issue 8995, 1996, Pages 196-

  Montastruc, J L ^a   Rascol, O ^a   Senard, J M ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT;

HUMAN; LETTER; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0030042393     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90381-5     Document Type: Letter

References (5)

1. H. Yamashita H. Kawakami Y-X. Zhang K. Tanaka S. Nakamura Neuroprotective mechanism of bromocriptine Lancet 346 1995 1305
2. Jl Montastruc O. Rascol Jm Senard A. Rascol A randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up J Neurol Neurosurg Psychiatry 57 1994 1034 1038
3. The Parkinson's Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease N Engl J Med 328 1993 178 183
4. Aj Lees Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease BMJ 311 1995 1602 1607 on behalf of the Parkinson's Disease Research Group of the United Kingdom
5. Cw Olanow Ra Hauser L. Ganger The effect of deprenyl and levodopa on the progression of Parkinson's disease Ann Neurol 38 1995 771 777